![]() ![]() Specifically, it is superior to CA125 in detecting borderline and early-stage OC, and has been approved for evaluating follow-up and recurrence of OC patients ( 18– 23).Īt present, there is a lack of reports on the combined diagnosis of the IOTA ADNEX model and HE4. Human epithelial protein 4 (HE4) is a highly recognized clinical marker for epithelial ovarian tumors after CA125 and usually applied in combination with CA125 to determine the benignity and malignancy of ovarian tumors. A cutoff risk of 10% was mostly recommended in research, which has a high sensitivity (>90%) despite its low specificity (approximately 62%) ( 15, 16).ĭetecting ovarian epithelial cancer at an earlier stage may be possible by combining tumor markers ( 17). In addition, with regard to the IOTA ADNEX cutoff risk, the guidelines merely recommended the selection according to the type of center and the clinical characteristics of the patient, without an accurate value. Nevertheless, an ovarian borderline, a Stage I OC, or a metastatic ovarian tumor cannot be accurately differentiated with it ( 9– 14). Related research shows that the model discriminated well between benign tumors and each of the four types of malignancy, with AUCs ranging between 0.85 and 0.99. An explanation of how to apply the ADNEX model from the IOTA group for discriminating between different subtypes of adnexal tumors was provided by Van Calster et al. The IOTA group delivered the ADNEX model in 2014, which was the first to distinguish between benign ovarian tumors, borderline, invasive, and secondary metastatic cancers. Performing a suitable first surgical procedure is crucial for OC patients, which depends on the correct staging of the tumor before surgery. As per related studies, the IOTA ADNEX model is the most effective in differentiating benign from malignant ovarian tumors. To enhance the accuracy of ovarian tumor ultrasound diagnosis, a number of prediction models have been developed by the International Ovarian Tumor Analysis (IOTA) group utilizing logistic regression analysis, which include the LR1, LR2, and IOTA ADNEX (Assessment of Different NEoplasias in the adneXa) models ( 6– 8). In contrast, postoperative survival rates of early-stage OC can reach 92.6%, while early diagnosis accuracy is just 16.3% ( 5). ![]() The 5-year survival rate of advanced OC is about 30%, according to past reports. Ovarian cancer (OC), one type of gynecologic malignancy with a high mortality rate, has seriously threatened the life and health of women, whose incidence and mortality rate are gradually increasing over the years ( 1– 4). ![]() A significant difference was found in separating borderline masses from Stage II–IV OC ( p = 0.0257).Ĭonclusions: A combination of the IOTA ADNEX model and HE4 can improve the specificity of diagnosis of ovarian benign and malignant tumors and increase the sensitivity and effectiveness of the differential diagnosis of Stage II–IV OC and borderline tumors. The IOTA ADNEX model combined with HE4 was better at improving the accuracy of the differential diagnosis between different OCs than the IOTA ADNEX model alone. Results: The area under the curve (AUC) of the ADNEX model alone or combined with HE4 in predicting benign and malignant ovarian tumors was 0.914 (95% CI, 0.881–0.941) and 0.916 (95% CI, 0.883–0.942), respectively. We analyzed receiver operating characteristic curves to determine whether the IOTA ADNEX model alone or combined with HE4 provided better diagnostic accuracy. Based on the IOTA ADNEX model post-processing software, the risk prediction value was calculated. All cases were analyzed and the histopathological diagnosis serves as the reference standard. Ultrasonographic images, cancer antigen-125 (CA 125) levels, and HE4 levels were obtained. Methods: A total of 376 women who were hospitalized and operated on in Women and Children’s Hospital of Chongqing Medical University were selected. Objective: This work was designed to investigate the performance of the International Ovarian Tumor Analysis (IOTA) ADNEX (Assessment of Different NEoplasias in the adneXa) model combined with human epithelial protein 4 (HE4) for early ovarian cancer (OC) detection.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |